{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'The skeletal survey should include a lateral radiograph of the skull, anterioposterior and lateral', 'views of the spine, and anterioposterior views of the pelvis, ribs, femora, and humeri.', 'If lytic bone lesions or plasmacytomas are observed at baseline, their number and size should be', 'recorded in the eCRF. Bone lesions and/or plasmacytomas detected by imaging at baseline', 'should be reassessed during the study, at a frequency determined by the Investigator, using the', 'same imaging modality that was used at baseline to document response.', 'For patients without soft tissue plasmacytomas (ie, bone lesions only), skeletal survey', 'by X-rays or low-dose CT should be performed. Contrast is not required.', 'For patients with soft tissue plasmacytomas, skeletal survey by X-rays or low-dose', 'CT should be performed (contrast not required) and in addition MRI or CT or', 'PET/CT, usually requiring contrast enhancement, should be performed.', 'Skeletal imaging does not need to be repeated in Cycle 1.', 'Skeletal survey results will be read by the local laboratory. Refer to the Study Manual for details.', '11.3.1.8. Clinical Plasmacytoma Assessment', 'If plasmacytomas are detected at baseline by physical examination/palpation, they should be', 'counted and measured per IMWG guidelines and recorded, and then reassessed as clinically', 'indicated during the symptom-directed physical examinations.', '11.3.1.9. Bone Marrow Aspirate', 'A bone marrow aspirate will be collected at Screening and a portion will be provided to the', 'central laboratory for karyotyping and fluorescence in situ hybridization (FISH) analysis to', 'confirm diagnosis and classify cytogenetic MM subtypes for R-ISS staging.', 'Another portion of the Screening bone marrow aspirate will be used to isolate plasma, non-tumor', 'CD138- and tumor CD138+ cell fractions for future PDn testing (see Section 11.4.2.1).', 'Evaluation of cytogenetic alterations will include deletion of 17p [del(17p)], a translocation of', 'chromosome [t(4;14)], a translocation of chromosome 14 and chromosome 16 [t(14;16)], and', 'chromosome 1q21 amplification.', 'A bone marrow aspirate is required at the time of response for the MRD test for patients in either', 'arm who achieve CR or sCR, unless after consultation with the Medical Monitor the collection', 'and/or processing of the sample is not considered to be feasible.', 'A portion of the bone marrow aspirate collected at the time of response will be provided to the', 'central laboratory. Refer to the Study Manual for details.', 'MRD will be assessed by fluorescence activated cell sorting (FACS) of bone marrow aspirates.', 'MRD results will be quantitative: MRD positive = number of malignant clones per', '100,000 leukocytes >0; MRD negative = number of malignant clones per 100,000 leukocytes', '= - 0.', 'Bone marrow aspiration may also be performed, as clinically indicated, to assess progression.', 'Confidential', 'Page 79', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '11.3.1.10. Bone Marrow Core (Trephine) Biopsy', 'At the time of response, a bone marrow core (trephine) biopsy is required to confirm CR and', 'sCR.', 'A tissue block collected at the time of response for patients in either arm who achieve CR or sCR', 'will be provided to the central laboratory. Refer to the Study Manual for details.', 'A bone marrow core (trephine) biopsy may also be performed, as clinically indicated, to assess', 'progression.', '11.4.', 'Pharmacokinetic and Pharmacodynamie Procedures', '11.4.1.', 'Pharmacokinetic Enppoints', 'PK sampling will only be performed at selected investigational sites that can accommodate', 'patients for up to 4 hours.', 'PK sampling for bortezomib will be performed for up to 25 patients in the Vd Arm.', 'PK sampling for bortezomib and selinexor will be performed for up to 25 patients in', 'the SVd Arm.', 'Blood draws for PK analysis will be performed in accordance with Table 18. For the SVd Arm,', 'selinexor should be dosed within 15 minutes prior to bortezomib on C2D15.', 'Details of PK sample collection and processing can be found in the Study Manual.', 'Plasma samples will be analyzed via validated methods for plasma bortezomib and selinexor', 'concentrations.', 'PK endpoints may include, but are not limited to, estimations of Cmax, AUC, and tmax.', 'Table 18:', 'Collection Time Points for Bortezomib and Selinexor PK', 'Time Points for PK Sample Collection', 'Vd Arm', 'SVd Arm', '(bortezomib', '(bortezomib and', 'PK)', 'selinexor PK)', 'C2D11', 'C2D15a', 'Predose (before dosing of bortezomib in the Vd', 'X', 'X', 'Arm and before dosing of selinexor and', 'bortezomib in the SVd Arm)', '30 min ( 5 min) post-bortezomib dose', 'X', 'X', '1 hr ( 10 min) post-bortezomib dose', 'X', 'X', '2 hr ( 10 min) post-bortezomib dose', 'X', 'X', '4 hr ( 10 min) post-bortezomib dose (if', 'X', 'X', 'feasible)', 'Abbreviations: hr = hours; min = minutes; PK = pharmacokinetics; SVd = selinexor plus bortezomib', 'plus low-dose dexamethasone; Vd = bortezomib plus low-dose dexamethasone.', 'a Selinexor should be dosed within 15 minutes prior to bortezomib on C2D15.', 'Confidential', 'Page 80', 'Version 4.0']\n\n###\n\n", "completion": "END"}